Skip to main content

TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings

Written by Customer Service on . Posted in Public Companies.

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 56th American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually May 29 – June 1, 2020 and the 25th European Hematology Association (EHA) annual congress, to be held virtually June 11 – 14, 2020. Details of the data presentations are included below.
Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are extremely pleased to present data from three combination trials at the upcoming June conferences, which we believe underscores the progress we have made in our combinatorial approach, as well as the potential utility of our lead drug candidates in oncology. We are particularly excited to share the final results from the GENUINE Phase 3 trial, evaluating ublituximab in high-risk CLL patients, which is the first randomized trial to demonstrate a PFS benefit with the addition of an anti-CD20 antibody to ibrutinib, compared to ibrutinib monotherapy. Additionally, it is encouraging to see long-term results from the combination of umbralisib and ibrutinib continue to show the potential versatility of umbralisib in combination regimens.“ Mr. Weiss continued, “Lastly, we look forward to presenting updated results from our proprietary triple combination of ublituximab, umbralisib, and our highly selective, BTK inhibitor, TG-1701, which to date has shown encouraging clinical activity at all dose levels evaluated.”Data to be presented at the ASCO meeting:Presentation Title: Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III studyAbstract Number: 7506Available on Demand: Friday, May 29, 2020 at 8:00 AM ETSession Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic LeukemiaLead Author: Jeff P. Sharman, MD, Willamette Valley Cancer Institute, US Oncology Research, Eugene, ORThe above abstract is now available via the ASCO meeting website at www.asco.org.Data to be presented at the EHA meeting:Presentation Title: Long term results of a Phase I/Ib study of ibrutinib in combination with umbralisib in patients with relapsed/refractory CLL or MCLAbstract Number: EP689Available on Demand: Friday, June 12, 2020 at 8:30 CESTSession Title: Chronic lymphocytic leukemia and related disorders – ClinicalLead Author: Matthew Davids, MD, MMSc, Medical Oncology, Dana Farber Cancer Institute, Boston, MAPresentation Title: Safety and activity of the once daily selective bruton tyrosine kinase (BTK) inhibitor TG-1701 in patients with chronic lymphocytic leukemia (CLL) and lymphomaAbstract Number: EP705Available on Demand: Friday, June 12, 2020 at 8:30 CESTSession Title: Chronic lymphocytic leukemia and related disorders – ClinicalLead Author: Chan Cheah, MD, Haematology, Linear Clinical Research, and Sir Charles Gardiner Hospital, Nedlands, Australia
The above abstracts are now available via the EHA meeting website at www.ehaweb.org.Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.